bluebird bio (BLUE) Reports First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study – StreetInsider.com
|
bluebird bio (BLUE) Reports First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study
StreetInsider.com bluebird bio, Inc. (NASDAQ: BLUE) announced the treatment of the first patient with relapsed/refractory multiple myeloma in a Phase 1 study of bb21217. bb21217 is an investigational chimeric antigen receptor T cell (CAR T) therapy targeting B cell … |
